Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)-MedSci.cn

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Zhou, CC; Wu, L; Fan, Y; Wang, ZH; Liu, LK; Chen, GY; Zhang, L; Huang, DZ; Cang, SD; Yang, ZX; Zhou, JY; Zhou, CZ; Li, BL; Li, J; Fan, M; Cui, JW; Li, YP; Zhao, H; Fang, J; Xue, JX; Hu, CP; Sun, P; Du, YY; Zhou, H; Wang, SY; Zhang, W

Zhou, CC (corresponding author), Univ Shanghai, Dept Oncol, Pulm Hosp, 507 Zhengmin Rd, Shanghai 200082, Peoples R China.

Abstract

Introduction: The standard chemotherapy for squamous NSCLC (sqNSCLC) includes platinum plus gemcitabine. Sintilimab, an anti-programmed cell death pro......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

科室

工具

服务